Senti Biosciences Announces Executive Leadership Restructuring
PremiumCompany AnnouncementsSenti Biosciences Announces Executive Leadership Restructuring
6M ago
Senti Bio announces first patient dosed in Phase 1 trial of SENTI-202
Premium
The Fly
Senti Bio announces first patient dosed in Phase 1 trial of SENTI-202
6M ago
Senti Biosciences Announces Executive Team Reshuffle and New CFO
Premium
Company Announcements
Senti Biosciences Announces Executive Team Reshuffle and New CFO
6M ago
Senti Bio announces 37% headcount reduction
PremiumThe FlySenti Bio announces 37% headcount reduction
10M ago
Senti Bio announces FDA clearance of IND application for SENTI-202
Premium
The Fly
Senti Bio announces FDA clearance of IND application for SENTI-202
11M ago
Senti Bio reports Q3 EPS (34c), consensus (44c)
Premium
The Fly
Senti Bio reports Q3 EPS (34c), consensus (44c)
1y ago
Senti Bio highlights preclinical data from cell therapy programs at AACR meeting
PremiumThe FlySenti Bio highlights preclinical data from cell therapy programs at AACR meeting
2y ago
Senti Bio price target lowered to $2 from $3 at Morgan Stanley
Premium
The Fly
Senti Bio price target lowered to $2 from $3 at Morgan Stanley
2y ago
Senti Bio price target lowered to $7 from $8 at Chardan
Premium
The Fly
Senti Bio price target lowered to $7 from $8 at Chardan
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100